At Rush University Medical Center, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.

Excellence is just the beginning.


French German Italian Portuguese Russian

Treatment Study of Intracranial Dural Arteriovenous Fistulas

Clinical Trial Title: 
PHIL dAVF: Study of Phil® Embolic System in the treatment of intracranial dural arteriovenous fistulas.
Clinical Trial Protocol ID: 
Clinical Trial Investigator Name: 
Michael Chen, MD
Clinical Trial Protocol Description: 

This study is a prospective, multicenter, single-arm study. Patients with dural arteriovenous fistulas (dAVF) have a few choices for safe treatment. In this study, all patients with qualifying dAVFs will be treated with PHIL® Liquid Embolic material.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Are between 22 and 80 years of age.
  • Are willing and capable of complying with all study protocol requirements, including specified follow-up period.
  • Provide written informed consent (subject or authorized legal representative) prior to initiation of any study procedures.
  • Have an intracranial dAVF.

You will be excluded from the study if any of the following criteria apply to you:

  • Have multiple dAVFs to be treated.
  • Have a history of life threatening allergy to contrast media (unless treatment for allergy is tolerated).
  • Have known allergies to dimethylsulfoxide, iodine.
  • Are currently participating in another clinical study

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Stroke and Cerebrovascular Disease
Contact Phone: 
(312) 942-8681
Contact Name: 
Kevin Keegan